"Illinois Retina Associates is committed to excellence. We are one of the leading retina practices in the US devoted to diagnosing & treating diseases of the retina, macula & vitreous. Our retina specialists also have more than a centry of experience in treating macular degeneration, diabetic retinopathy, vascular retinal detachments, flashes & floaters, uveitis, ocular oncology & more. We use state of the art testing & treatments including retinal laser treatment, fluorescein angiography, optical coherence tomography, ultrasound & intravitreal injections. We participate in national & international clinical trials & research studies and participate in a 2-year fellowship program in conjunction with Rush University Medical Center."

During the past decade, Illinois Retina Associates, S.C. conducted 10 clinical trials. In the 10-year time frame, 10 clinical trials started and 6 clinical trials were completed, i.e. on average, 60% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 6 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Illinois Retina Associates, S.C." #1 sponsor was "Jaeb Center for Health Research" with 4 trials, followed by "Aerpio Therapeutics" with 1 trials sponsored, "Alimera Sciences" with 1 trials sponsored, "Clearside Biomedical, Inc." with 1 trials sponsored and "Gilead Sciences" with 1 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Illinois Retina Associates, S.C." #1 collaborator was "National Eye Institute (NEI)" with 2 trials as a collaborator, "National Institutes of Health (NIH)" with 2 trials as a collaborator, "Galapagos NV" with 1 trials as a collaborator, "Kowa Company, Ltd." with 1 trials as a collaborator and "Novartis Pharmaceuticals" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Illinois Retina Associates, S.C." are "Diabetic Macular Edema" (3 trials), "Age-Related Macular Degeneration" (1 trials), "Diabetic Macular Edema (DME)" (1 trials), "Diabetic Retinopathy" (1 trials) and "Full-thickness Macular Holes (MH)" (1 trials). Many other conditions were trialed in "Illinois Retina Associates, S.C." in a lesser frequency.

Most popular intervention types in "Illinois Retina Associates, S.C." are "Drug" (9 trials), "Device" (2 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (2 trials), "Ranibizumab" (2 trials), "4mg CLS-TA Suprachoriodal Injection" (1 trials), "AKB-9778" (1 trials) and "Bevacizumab + Deferred Aflibercept Group" (1 trials). Other intervention names were less common.

The vast majority of trials in "Illinois Retina Associates, S.C." are 11 trials for "All" genders.

Currently, there are NaN active trials in "Illinois Retina Associates, S.C.". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 8 completed trials in Illinois Retina Associates, S.C., undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Illinois Retina Associates, S.C., 1 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 1 trials that are defined as “Not Applicable".